Quick Answer
KYNTRA BIO, INC. reported Total Revenue of $6.44 million for fiscal year 2025.
KYNTRA BIO, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.44M -78.3% |
$29.62M -36.7% |
$46.80M -66.7% |
$140.73M -40.2% |
$235.31M +33.5% |
$176.32M -31.3% |
| Revenue (ASC 606) | $6.44M -78.3% |
$29.62M -36.7% |
$46.80M -66.7% |
$140.73M -40.2% |
$235.31M +33.5% |
$176.32M -31.3% |
| Net Income | $183.45M +485.6% |
-$47.58M +83.3% |
-$284.23M +3.2% |
-$293.65M -1.3% |
-$290.02M -53.2% |
-$189.29M -145.9% |
| Diluted EPS | $45.37 +481.6% |
-$11.89 -307.2% |
-$2.92 +7.0% |
-$3.14 +0.0% |
-$3.14 -48.8% |
-$2.11 |
| Total Assets | $119.59M -44.3% |
$214.53M -49.3% |
$423.53M -30.6% |
$610.09M -21.2% |
$773.82M -6.4% |
$826.84M -3.6% |
| Cash and Equivalents | $47.87M -5.2% |
$50.48M -38.1% |
$81.55M -47.6% |
$155.70M -9.1% |
$171.22M -74.8% |
$678.39M +437.3% |
| Stockholders Equity | -$30.04M +86.7% |
-$225.60M -10.5% |
-$204.17M -852.0% |
-$21.45M -110.3% |
$209.15M -50.5% |
$422.18M -18.2% |
| R&D Expense | $23.52M -75.4% |
$95.69M -64.1% |
$266.47M -10.2% |
$296.79M -23.3% |
$387.04M +53.0% |
$252.92M +20.9% |
| Operating Income | -$45.90M +69.5% |
-$150.42M +53.4% |
-$322.72M -7.2% |
-$301.02M -4.3% |
-$288.53M -50.4% |
-$191.88M -114.8% |
| Shares Outstanding | 4.05M +0.2% |
4.04M -95.9% |
98.77M +4.9% |
94.17M +1.4% |
92.88M +1.6% |
91.44M +4.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.08M | +774.8% | -20.2% |
| Revenue (ASC 606) | September 30, 2025 | $1.08M | +774.8% | -20.2% |
| Net Income | September 30, 2025 | $200.64M | +1274.4% | +2738.9% |
| Diluted EPS | September 30, 2025 | $49.61 | +1267.3% | +2738.8% |
| Total Assets | September 30, 2025 | $137.01M | -48.2% | -23.0% |
| Cash and Equivalents | September 30, 2025 | $117.97M | -9.9% | +404.9% |
| Stockholders Equity | September 30, 2025 | -$17.03M | +93.0% | +92.4% |
| R&D Expense | September 30, 2025 | $1.21M | -93.9% | -79.4% |
| Operating Income | September 30, 2025 | -$5.41M | +88.7% | +55.1% |
| Shares Outstanding | September 30, 2025 | 4.04M | -96.0% | +0.0% |
- KYNTRA BIO, INC. reported Total Revenue of $6.44 million for fiscal year 2025.
- KYNTRA BIO, INC. showed a decrease of -78.3% in Total Revenue compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Revenue (ASC 606) of $6.44 million for fiscal year 2025.
- KYNTRA BIO, INC. showed a decrease of -78.3% in Revenue (ASC 606) compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Net Income of $183.45 million for fiscal year 2025.
- KYNTRA BIO, INC. showed an increase of +485.6% in Net Income compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Diluted EPS of $45.37 per share for fiscal year 2025.
- KYNTRA BIO, INC. showed an increase of +481.6% in Diluted EPS compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Total Assets of $119.59 million for fiscal year 2025.
- KYNTRA BIO, INC. showed a decrease of -44.3% in Total Assets compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Cash and Equivalents of $47.87 million for fiscal year 2025.
- KYNTRA BIO, INC. showed a decrease of -5.2% in Cash and Equivalents compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Stockholders Equity of -$30.04 million for fiscal year 2025.
- KYNTRA BIO, INC. showed an increase of +86.7% in Stockholders Equity compared to the prior fiscal year.
- KYNTRA BIO, INC. reported R&D Expense of $23.52 million for fiscal year 2025.
- KYNTRA BIO, INC. showed a decrease of -75.4% in R&D Expense compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Operating Income of -$45.90 million for fiscal year 2025.
- KYNTRA BIO, INC. showed an increase of +69.5% in Operating Income compared to the prior fiscal year.
- KYNTRA BIO, INC. reported Shares Outstanding of 4.05 million shares for fiscal year 2025.
- KYNTRA BIO, INC. showed an increase of +0.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: